1 week Ago By ABMN Staff
Wellington Management Group LLP decreased its stake in shares of Illumina, Inc. ( NASDAQ:ILMN – Free Report ) by 18.3% in the 4th quarter, HoldingsChannel.
com reports. The institutional investor owned 25,298 shares of the life sciences company’s stock after selling 5,648 shares during the quarter. Wellington Management Group LLP’s holdings in Illumina were worth $3,381,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in ILMN. Kovitz Investment Group Partners LLC acquired a new position in Illumina in the 3rd quarter valued at about $414,000. XTX Topco Ltd purchased a new stake in shares of Illumina during the third quarter worth about $226,000.
MML Investors Services LLC raised its position in shares of Illumina by 4.4% in the third quarter. MML Investors Services LLC now owns 23,373 shares of the life sciences company’s stock valued at $3,048,000 after buying an additional 990 shares during the last quarter.
Nomura Asset Management Co. Ltd. lifted its stake in shares of Illumina by 8.
8% during the third quarter. Nomura Asset Management Co. Ltd.
now owns 50,593 shares of the life sciences company’s stock valued at $6,598,000 after buying an additional 4,077 shares during the period. Finally, Geode Capital Management LLC boosted its position in Illumina by 1.8% during the third quarter.
Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after acquiring an additional 48,018 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets Several research analysts have weighed in on ILMN shares. Stephens reiterated an “overweight” rating and issued a $156.00 price target on shares of Illumina in a report on Tuesday, March 11th.
Guggenheim dropped their target price on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th.
Barclays decreased their price target on Illumina from $100.00 to $77.00 and set an “underweight” rating on the stock in a research note on Thursday.
Citigroup lowered their price target on Illumina from $90.00 to $85.00 and set a “neutral” rating for the company in a report on Monday, April 7th.
Finally, Canaccord Genuity Group cut their price objective on shares of Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a report on Tuesday, March 11th.
One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $138.70.
Illumina Stock Up 4.9 % Shares of NASDAQ ILMN opened at $74.78 on Friday.
The stock has a fifty day moving average price of $88.58 and a 200 day moving average price of $122.32.
The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.
63. Illumina, Inc. has a 12-month low of $68.
70 and a 12-month high of $156.66. The company has a market cap of $11.
85 billion, a P/E ratio of -9.74, a P/E/G ratio of 1.60 and a beta of 1.
38. Illumina ( NASDAQ:ILMN – Get Free Report ) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.
86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06).
Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%.
Research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.
Illumina Company Profile ( Free Report ) Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
See Also Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. ( NASDAQ:ILMN – Free Report ).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter ..
